UNSPSC 51383511: Pravadoline maleate

This classification denotes a cyclooxygenase inhibitor with the molecular formula C23H26N2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2DH4X8278M, chemically known as methanone, (4-methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1h-indol-3-yl)- but more generally known as pravadoline maleate, which bears US NIH Compound Identifier 56463. Most nations, for tariff and trade purposes, schedule pravadoline maleate under HS 29349990 and SITC 51579.

As of Q4 2014, PRAVADOLINE MALEATE remains US FDA's Preferred Term for this commodity. Pravadoline maleate bears US NLM identifiers UMLS ID C0209364 and NCI Concept Code C81065. SMILES: CC1C(C2CCCCC2N1CCN3CCOCC3)C(=O)C4CCC(CC4)OC.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51383511 Pravadoline maleate is a Commodity code that in recent state and local procurement activity appears primarily associated with naloxone and related emergency pharmaceutical and drug-management products rather than pravadoline specifically. State and local governments buying under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances seeking to procure emergency medications, over-the-counter pharmaceuticals, and drug deactivation systems to support community health and substance-abuse response initiatives. The scope of work centers on bulk purchase and distribution of FDA-compliant pharmaceuticals and related products through authorized wholesaler networks, with vendors required to maintain cGMP and Drug Supply Chain Security Act compliance, provide detailed National Drug Code and product specification data, and manage quarterly or ongoing deliveries to designated state or local facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building by July 26, 2023 response deadline. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, due March 26, 2026, requiring vendor compliance with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, with award effective July 1, 2026.